February 28, 2015 2:01 AM ET


Company Overview of NuRx Pharmaceuticals, Inc.

Company Overview

NuRx Pharmaceuticals, Inc. focuses on nuclear receptor target therapeutics for the treatment of cancer. The company’s lead compound, NRX 5183 is in the phase II clinical trial for the treatment of Relapsed Acute Promyelocytic Leukemia. It has a license agreement with Vitae Pharmaceuticals, Inc. to license certain compounds and nuclear receptor technology for human and veterinary use. The company has a joint venture agreement with QuantRX Biomedical Corporation to commercialize point-of-care products. NuRx Pharmaceuticals, Inc. was formerly known as Quest Group International Inc. and changed its name to NuRx Pharmaceuticals, Inc. in October 2007. The company was founded in 2001 and is based i...

18 Technology Drive

Suite 130

Irvine, CA 92618

United States

Founded in 2001

3 Employees





Key Executives for NuRx Pharmaceuticals, Inc.

Chief Executive Officer, President and Director
Age: 57
Executive Director and Member of Nominating Committee
Age: 55
Chief Medical Officer and Member of the Scientific Advisory Board
Age: 63
Secretary, Director, Member of Audit Committee, Member of Nominating Committee and Member of Compensation Committee
Age: 46
Director of Clinical Affairs
Compensation as of Fiscal Year 2014.

NuRx Pharmaceuticals, Inc. Key Developments

SEC Revokes Registration Of Registered Securities Of NuRx Pharmaceuticals

An Administrative Law Judge has issued an Initial Decision of Default as to NuRx Pharmaceuticals, Inc. The Initial Decision found that the company was issuer of securities registered pursuant to Section 12(g) of the Securities Exchange Act of 1934 (Exchange Act), and the company failed to comply with Section 13(a) of the Exchange Act and Exchange Act Rules 13a-1 and/or 13a-13 by not filing required periodic reports with the Securities and Exchange Commission (SEC). The Initial Decision finds these allegations to be true and revokes the registration of each class of the company’s registered securities, pursuant to Section 12(j) of the Securities Exchange Act of 1934.

SEC Orders Hearings On Registration Suspension Or Revocation Against NuRx Pharmaceuticals, Inc. For Failure To Make Required Periodic Filings

Securities and Exchange Commission (SEC or the commission) instituted public administrative proceeding to determine whether to revoke or suspend for a period not exceeding twelve months the registration of each class of the securities of NuRx Pharmaceuticals, Inc. for failure to make required periodic filings with the Commission. In this Order, the Division of Enforcement (Division) alleges that the company was delinquent in its required periodic filings with the Commission. In this proceeding, instituted pursuant to Exchange Act Section 12(j), a hearing will be scheduled before an Administrative Law Judge. At the hearing, the judge will hear evidence from the Division and the company to determine whether the allegations of the Division contained in the Order, which the Division alleges constitute failures to comply with Exchange Act Section 13(a) and Rules 13a-1 and 13a-13 there under, are true. The judge in the proceeding will then determine whether the registrations pursuant to Exchange Act Section 12 of each class of the securities of the company should be revoked or suspended for a period not exceeding twelve months. The Commission ordered that the Administrative Law Judge in this proceeding issue an initial decision not later than 120 days from the date of service of the order instituting proceeding.

Similar Private Companies By Industry

Company Name Region
ConjuGon Inc. United States
AB Advanced Genetic Analysis Corporation United States
ProhibiTx, Inc. United States
Light Biology Inc. United States
Stowers Institute For Medical Research Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NuRx Pharmaceuticals, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.